Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-021-02103-7 ◽

2022 ◽

Author(s):

Hiroki Nasu ◽

Shin Nishio ◽

Jongmyung Park ◽

Teruyuki Yoshimitsu ◽

Ken Matsukuma ◽

...

Keyword(s):

Ovarian Cancer ◽

Platinum Resistant

A molecular signature for identification of platinum resistant ovarian cancer

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0028-1088857 ◽

2008 ◽

Vol 68 (S 01) ◽

Author(s):

T Fehm ◽

M Bonin ◽

J Hoffmann ◽

K Sotlar ◽

E Solomayer ◽

...

Keyword(s):

Ovarian Cancer ◽

Molecular Signature ◽

Platinum Resistant

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0034-1388557 ◽

2014 ◽

Vol 74 (S 01) ◽

Author(s):

F Hilpert ◽

C Kurzeder ◽

B Schmalfeldt ◽

P Neuser ◽

N de Gregorio ◽

...

Keyword(s):

Ovarian Cancer ◽

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Multicenter Phase ◽

Platinum Resistant ◽

Recurrent Endometrial Cancer

The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592664 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

C Mayer ◽

M Schmidt ◽

EM Grischke ◽

G Gebauer ◽

HC Fricke ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Multicenter Phase ◽

Platinum Resistant ◽

Metronomic Cyclophosphamide

COMPARISON OF GENE MUTATIONAL ANALYSES, INCLUDING BRCA1 ALTERATIONS, IN TWO PROSPECTIVE STUDIES IN NEWLY DIAGNOSED VERSUS PLATINUM-RESISTANT OVARIAN CANCER

10.26226/morressier.599bdc7ad462b80296ca1917 ◽

2017 ◽

Author(s):

Regula Deurloo

Keyword(s):

Ovarian Cancer ◽

Prospective Studies ◽

Newly Diagnosed ◽

Platinum Resistant

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Case Medical Research ◽

10.31525/ct1-nct03949283 ◽

2019 ◽

Author(s):

Keyword(s):

Ovarian Cancer ◽

Stem Cell ◽

Cancer Stem Cell ◽

Cell Assay ◽

Platinum Resistant

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Case Medical Research ◽

10.31525/ct1-nct04217798 ◽

2020 ◽

Author(s):

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Oral Etoposide ◽

Efficacy And Safety ◽

Resistant Refractory ◽

Platinum Resistant

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Faculty Opinions recommendation of Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718128610.793486222 ◽

2013 ◽

Author(s):

David Kushner ◽

Erin Medlin

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community

Seminars in Cancer Biology ◽

10.1016/j.semcancer.2021.02.009 ◽

2021 ◽

Author(s):

Marco Petrillo ◽

Giulio Sozzi ◽

Margherita Dessole ◽

Giampiero Capobianco ◽

Salvatore Dessole ◽

...

Keyword(s):

Ovarian Cancer ◽

Scientific Community ◽

Platinum Resistant

Predicting response to platinum and non-platinum drugs through bioluminescence resonance energy transfer (BRET) based bio-molecular interactions in platinum resistant epithelial ovarian cancer

Translational Oncology ◽

10.1016/j.tranon.2021.101193 ◽

2021 ◽

Vol 14 (11) ◽

pp. 101193

Author(s):

Aniketh Bishnu ◽

Megha Mehrotra ◽

Ajit Dhadve ◽

Shalini Dimri ◽

Abhijit De ◽

...

Keyword(s):

Ovarian Cancer ◽

Energy Transfer ◽

Epithelial Ovarian Cancer ◽

Molecular Interactions ◽

Resonance Energy Transfer ◽

Resonance Energy ◽

Platinum Drugs ◽

Bioluminescence Resonance Energy Transfer ◽

Platinum Resistant